Wen-Shuo Wu

637 total citations · 1 hit paper
22 papers, 427 citations indexed

About

Wen-Shuo Wu is a scholar working on Urology, Epidemiology and Molecular Biology. According to data from OpenAlex, Wen-Shuo Wu has authored 22 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Urology, 5 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Wen-Shuo Wu's work include Hair Growth and Disorders (11 papers), Autoimmune Bullous Skin Diseases (4 papers) and Autoimmune and Inflammatory Disorders (4 papers). Wen-Shuo Wu is often cited by papers focused on Hair Growth and Disorders (11 papers), Autoimmune Bullous Skin Diseases (4 papers) and Autoimmune and Inflammatory Disorders (4 papers). Wen-Shuo Wu collaborates with scholars based in United States, Japan and Taiwan. Wen-Shuo Wu's co-authors include LiMin Fu, Yuh‐Min Chen, Yves Dutronc, Rodney Sinclair, Brett King, Jill Shwed McCollam, Ohsang Kwon, Chen‐Yen Lin, Yu‐Chin Lee and Guanglei Yu and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Wen-Shuo Wu

22 papers receiving 406 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

2023 65 citations Ohsang Kwon, Maryanne M. Senna et al. American Journal of Clinical Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wen-Shuo Wu United States	11	134	125	72	71	60	22	427
Yun‐Ting Chang Taiwan	13	117 0.9×	32 0.3×	7 0.1×	82 1.2×	153 2.5×	30	427
Anders Ljungberg Sweden	8	118 0.9×	9 0.1×	12 0.2×	40 0.6×	58 1.0×	11	343
Parviz Toossi Iran	13	167 1.2×	18 0.1×	3 0.0×	90 1.3×	53 0.9×	31	363
C. Abasq France	7	92 0.7×	9 0.1×	6 0.1×	174 2.5×	136 2.3×	29	358
Sophie Momen United Kingdom	10	98 0.7×	5 0.0×	3 0.0×	114 1.6×	43 0.7×	16	494
Marco Di Fraia Italy	11	139 1.0×	53 0.4×		45 0.6×	12 0.2×	25	396
Ragıp Ertaş Türkiye	11	127 0.9×	17 0.1×	2 0.0×	159 2.2×	277 4.6×	40	414
Maryte Papadopoulos United States	10	426 3.2×	7 0.1×	11 0.2×	27 0.4×	68 1.1×	14	625
Hala Mégarbané Lebanon	12	34 0.3×	60 0.5×	2 0.0×	17 0.2×	46 0.8×	24	495
Mario Mitkov United States	8	67 0.5×	10 0.1×	2 0.0×	8 0.1×	30 0.5×	14	286

Countries citing papers authored by Wen-Shuo Wu

Since Specialization

Citations

This map shows the geographic impact of Wen-Shuo Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen-Shuo Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen-Shuo Wu more than expected).

Fields of papers citing papers by Wen-Shuo Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen-Shuo Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen-Shuo Wu. The network helps show where Wen-Shuo Wu may publish in the future.

Co-authorship network of co-authors of Wen-Shuo Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wen-Shuo Wu. A scholar is included among the top collaborators of Wen-Shuo Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen-Shuo Wu. Wen-Shuo Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Corren, Jonathan, Stanley J. Szefler, Ellen Sher, et al.. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1215–1224.e3. 18 indexed citations

Taylor, Susan C., Neil J. Korman, Tsen‐Fang Tsai, et al.. (2023). Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2. Dermatology and Therapy. 13(12). 3181–3191. 7 indexed citations

King, Brett, Jerry Shapiro, Manabu Ohyama, et al.. (2023). Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib. SKIN The Journal of Cutaneous Medicine. 7(2). s184–s184. 1 indexed citations

King, Brett, Manabu Ohyama, Maryanne M. Senna, et al.. (2023). 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2. Journal of the American Academy of Dermatology. 89(3). AB69–AB69. 1 indexed citations

King, Brett, Jerry Shapiro, Manabu Ohyama, et al.. (2023). When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal of Dermatology. 189(6). 666–673. 25 indexed citations

Kwon, Ohsang, Maryanne M. Senna, Rodney Sinclair, et al.. (2023). Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). American Journal of Clinical Dermatology. 24(3). 443–451. 65 indexed citations breakdown →

Torrelo, Antonio, Barbara Rewerska, Amy S. Paller, et al.. (2023). Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). British Journal of Dermatology. 189(1). 23–32. 48 indexed citations

King, Brett, Justin Ko, Bianca Maria Piraccini, et al.. (2023). 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure. Journal of the American Academy of Dermatology. 89(3). AB220–AB220. 1 indexed citations

King, Brett, Justin Ko, Maryanne M. Senna, et al.. (2023). 42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib. Journal of the American Academy of Dermatology. 89(3). AB29–AB29. 1 indexed citations

10.

King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2022). Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. 188(2). 218–227. 37 indexed citations

11.

King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2022). 33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials. Journal of the American Academy of Dermatology. 87(3). AB176–AB176. 1 indexed citations

12.

Wu, Wen-Shuo, et al.. (2021). Breast cancer recurrence prediction with ensemble methods and cost-sensitive learning. Open Medicine. 16(1). 754–768. 22 indexed citations

13.

Paller, Amy S., Chia‐Yu Chu, Chin‐Yi Yang, et al.. (2021). 26585 Baricitinib for the treatment of pediatric patients with moderate-to-severe atopic dermatitis. Journal of the American Academy of Dermatology. 85(3). AB108–AB108. 2 indexed citations

14.

Senna, Maryanne M., Amy McMichael, Julian Mackay‐Wiggan, et al.. (2021). 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study. Journal of the American Academy of Dermatology. 85(3). AB85–AB85. 1 indexed citations

15.

Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2019). THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 308–309. 21 indexed citations

16.

Wu, Wen-Shuo, Shinn‐Liang Lai, Chao‐Hua Chiu, et al.. (2014). Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment. American Journal of Clinical Oncology. 39(6). 556–562. 4 indexed citations

17.

Wu, Wen-Shuo & Yuh‐Min Chen. (2014). Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. Journal of Personalized Medicine. 4(3). 297–310. 14 indexed citations

18.

Luo, Yung‐Hung, Wen-Shuo Wu, Wei‐Juin Su, et al.. (2011). Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. Journal of Thoracic Oncology. 7(2). 299–305. 49 indexed citations

19.

Fu, LiMin, et al.. (2009). Randomized Controlled Trials of Acupuncture for Neck Pain: Systematic Review and Meta-Analysis. The Journal of Alternative and Complementary Medicine. 15(2). 133–145. 69 indexed citations

20.

Singh, Betsy B, et al.. (2006). Effectiveness of acupuncture in the treatment of fibromyalgia.. PubMed. 12(2). 34–41. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact